Sun Pharmaceutical Industries cash flow

Latest FY26

Cash from operations: ₹12,419cr−11.7% on FY25
Capital spending: ₹3,609cr+69.6% on FY25
Free cash flow: ₹8,810cr−26.2% on FY25
Cash from financing: −₹2,513cr−₹7,906 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	2,938	2,575	2,557	2,529
	—	0.0	295	0.0	0.0
	—	339	231	238	172
	—	−915	−1,230	−1,023	−385
	—	−59.4	−66.9	−103	−146
	—	−876	−134	228	161
	—	−797	−337	−250	337
	—	253	199	228	192
	—	0.0	−413	−320	−138
	—	−52.3	−184	599	−1,202
	—	−2,009	−1,602	353	−953
	—	−210	−59.3	−384	−216
	—	1,057	528	250	1,182
	—	175	182	241	−669
	—	−230	812	3.7	−3,804
Cash from operating activities
	16,045	15,119	13,752	11,088	9,408
	—	−386	797	2,617	−2,939
	—	14,733	14,549	13,704	6,469
	—	2,314	477	1,569	1,510
	—	12,419	14,072	12,135	4,959
Cash from investing activities
	—	3,609	2,129	2,202	2,086
	—	96.1	61.0	30.8	21.0
	—	30,804	32,309	29,091	21,964
	—	26,167	29,418	30,094	20,897
	—	3,405	273	143	4,686
	—	0.0	3.4	20.7	0.0
	—	0.0	32.0	0.0	0.0
	—	59.4	66.0	99.1	132
	—	705	804	613	318
	—	−553	−973	−71.0	−576
	—	−11,344	−5,306	−690	−7,944
Cash from financing activities
	—	3.8	0.0	0.0	0.0
	—	5,322	3,362	4,716	8,160
	—	3,410	4,392	8,106	3,030
	—	151	135	123	135
	—	331	224	219	99.2
	—	3,938	3,617	2,901	2,520
	—	—	−3.3	−2.5	−0.9
	—	0.0	−2,900	−77.4	0.0
	—	−2,513	−7,906	−6,710	2,376
	—	−1,437	860	4,735	−608
	—	939	123	−72.7	724
	—	−498	983	4,662	115
	—	9,771	10,269	9,286	4,624
Reference items
	17,847	17,731	15,272	13,023	11,647
	29.8%	30.3%	29.1%	26.9%	26.5%
	8,810	8,810	11,944	9,933	2,874
	—	10,690	10,744	6,362	—
	₹36.72	₹36.72	₹49.78	₹41.40	₹11.98
	47.86×	—	—	—	—
	—	1.08×	1.28×	1.26×	0.58×
	—	2,314	477	1,569	1,510
	—	331	224	219	99.2

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SUNPHARMA₹1,757.50

Sun Pharmaceutical Industries Ltd.

· Pharma & Health

₹ CrorePeersCIPLA DRREDDY LUPIN APOLLOHOSP MAXHEALTH DIVISLAB TORNTPHARM ZYDUSLIFEMcap ₹4.22L Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	2,529.4	2,556.6	2,575.4	2,937.9	—
+ Impairment Loss / (Reversal)	0.0	0.0	295.3	0.0	—
+ Finance Costs	172.0	238.5	231.4	338.9	—
+ Interest Income	-384.5	-1,022.9	-1,230.1	-915.0	—
+ Dividend Income	-146.5	-103.3	-66.9	-59.4	—
+ Fair Value (Gains) / Losses	161.3	227.7	-133.8	-876.1	—
+ Unrealised FX (Gain) / Loss	336.8	-249.9	-336.7	-797.1	—
+ Other Non-cash Items	192.0	227.6	198.7	252.9	—
+ Other — Cash Effects are Investing / Financing	-138.0	-319.9	-413.0	0.0	—
Changes in Working Capital
+ Inventories	-1,202.2	598.8	-184.0	-52.3	—
+ Trade Receivables — Current	-953.2	352.9	-1,602.1	-2,008.8	—
+ Other Current Assets	-215.8	-383.9	-59.3	-209.6	—
+ Trade Payables — Current	1,182.4	249.7	528.0	1,057.4	—
+ Other Current Liabilities	-669.2	240.9	182.0	175.4	—
+ Provisions — Current	-3,803.9	3.7	811.8	-230.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	9,408.4	11,087.9	13,752.1	15,118.9	16,044.9
+ Total Adjustments (incl. Working Capital)	-2,939.3	2,616.5	796.8	-385.8	—
Cash from Operations (pre-tax)	6,469.2	13,704.4	14,548.9	14,733.1	—
+ Income Taxes Paid	1,509.8	1,569.4	476.8	2,313.9	—
Cash from Operating Activities	4,959.3	12,135.0	14,072.1	12,419.2	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	2,085.6	2,201.8	2,128.6	3,609.4	—
+ Disp of Fixed Assets	21.0	30.8	61.0	96.1	—
+ Purchase of Investments (Equity / Debt)	21,964.2	29,091.0	32,308.7	30,804.1	—
+ Sale of Investments (Equity / Debt)	20,896.8	30,094.5	29,417.5	26,167.4	—
+ Acq of Subsidiaries / Businesses (net)	4,685.8	143.3	272.8	3,405.1	—
+ Loans & Advances Made	0.0	20.7	3.4	0.0	—
+ Loans & Advances Repaid	0.0	0.0	32.0	0.0	—
+ Dividends Received — Investing	132.4	99.1	66.0	59.4	—
+ Interest Received — Investing	317.9	613.2	803.8	704.7	—
+ Other Inflows / (Outflows) — Investing	-576.2	-71.0	-973.0	-553.1	—
Cash from Investing Activities	-7,943.7	-690.2	-5,306.2	-11,344.1	—
Cash from Financing Activities
+ Payments — Change in Ownership of Subsidiaries	0.0	0.0	0.0	3.8	—
+ Proceeds from Borrowings	8,159.8	4,715.7	3,361.7	5,322.1	—
+ Repayment of Borrowings	3,030.1	8,105.6	4,392.0	3,410.2	—
+ Payment of Lease Liabilities	134.6	123.1	134.5	151.4	—
+ Interest Paid	99.2	219.0	223.8	331.5	—
+ Dividends Paid	2,519.7	2,900.7	3,617.3	3,937.8	—
+ Dividends Paid — Minority	-0.9	-2.5	-3.3	—	—
+ Other Inflows / (Outflows) — Financing	0.0	-77.4	-2,899.9	0.0	—
Cash from Financing Activities	2,376.1	-6,710.2	-7,905.8	-2,512.6	—
Net Changes in Cash (pre-FX)	-608.3	4,734.6	860.1	-1,437.4	—
+ Effect of FX Rate Changes on Cash	723.8	-72.7	123.0	939.2	—
Net Changes in Cash	115.5	4,661.9	983.1	-498.3	—
Closing Cash	4,623.7	9,285.7	10,268.8	9,770.5	—
Reference Items
EBITDA	11,646.8	13,023.1	15,271.7	17,731.4	17,847.4
EBITDA Margin %	26.54	26.85	29.05	30.33	29.79
Free Cash Flow (CFO − Capex)	2,873.8	9,933.2	11,943.5	8,809.8	8,809.8
Free Cash Flow to Equity	—	6,362.0	10,743.6	10,690.3	—
Free Cash Flow per Basic Share	11.98	41.40	49.78	36.72	36.72
Price to Free Cash Flow	—	—	—	—	47.86
Cash Flow to Net Income	0.58	1.26	1.28	1.08	—
Cash Paid for Taxes	1,509.8	1,569.4	476.8	2,313.9	—
Cash Paid for Interest	99.2	219.0	223.8	331.5	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 199%.